marked.bio

Company

Taiho Pharmaceutical

6 active trials that select patients by a biomarker on marked.bio, across 4 biomarkers; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

zipalertinib 3futibatinib 2zimberelimab 1ramucirumab 1bevacizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

6 of 12 trials shown

  1. A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

    Recruiting Phase 3 Taiho Pharmaceutical Started 2025Primary completion 2029-10 NCT07128199

    zipalertinib

    …Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

    EGFR exon 19 deletion / L858REGFR exon 20 insertionLung Cancer, Adjuvant, Post-surgical, EGFR

  2. REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

    Active, not recruiting Phase 3 Taiho Pharmaceutical Started 2023Primary completion 2027-05 NCT05973773

    zipalertinib

    Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation

    EGFR exon 19 deletion / L858REGFR exon 20 insertionAdvanced or Metastatic NSCLS With Exon 20 Insertion Mutation

  3. A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

    Recruiting Phase 2 Taiho Pharmaceutical Started 2023Primary completion 2028-08 NCT05967689

    zipalertinibCYP CocktailTransporter Cocktail

    common EGFRmt (eg, ex19del or L858R)

    EGFR exon 19 deletion / L858REGFR exon 20 insertionAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

  4. Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

    Recruiting Phase 2 Taiho Pharmaceutical Started 2023Primary completion 2026-12 NCT05727176

    futibatinib FDA EU

    Documented evidence of FGFR2 gene fusions or other FGFR2 rearrangement

    FGFR2 fusion or rearrangementAdvanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement

  5. Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

    Recruiting Phase 1/2 Taiho Pharmaceutical Started 2020Primary completion 2030-03 NCT04683250

    TAS0953/HM06

    Patient with RET gene fusion :

    RET fusion or mutationRET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors

  6. AB122 Platform Study

    Recruiting Phase 1 Taiho Pharmaceutical Started 2021Primary completion 2027-06 NCT04999761

    zimberelimabTAS-116futibatinibTAS-115trifluridine/tipiracilramucirumabbevacizumabfluorouracilcisplatinAB154carboplatinnab-paclitaxel

    …ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type. \[Mutant is defined as at least KRAS or NRAS mutant (any exon, any mutation)\].

    KRAS G12CKRAS G12DAdvanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer